hifibio-logo
  • About
  • Pipeline
  • DIS® Platform
  • Partnering
  • News
  • Join Us

News

  • About
    • Company Overview
    • Leadership
    • Scientific Advisory Board
    • Board of Directors
    • Scientific Founders
    • Contact
  • Pipeline
    • Overview
    • Overview
    • Programs
      • EMUNKITUG (HFB200301)
      • HFB200603
      • NUVUSTOTUG (HFB301001)
      • HFB200604
      • HFB3024
  • DIS® Platform
  • Partnering
  • News
  • Join Us

Latest News

Sep 25, 2025

HiFiBiO Therapeutics to Present Updated Phase 1 Clinical Data of Two Immuno-Oncology Programs at the 2025 Annual Meeting of the European Society for Medical Oncology (ESMO) 

ESMO-logo

All  Filter By:

Mar 30, 2020

Droplet Microfluidic Screening and Sequencing Can Vastly Expand the Universe of New Antibody Therapeutics

Jan 11, 2020

Biotechs Build on Single-cell Analytics for Drug R&D, as Human Cell Atlas is Mapped

Oct 28, 2019

HiFiBiO Therapeutics Establishes World-Class Scientific Advisory Board

Logo-RGB-72
Aug 28, 2019

HiFiBiO Therapeutics Closes $67 Million Series C Financing to Build on Recent Success and Advance Pipeline of Novel Antibody Drugs for Cancer and Autoimmune Disorders

Logo-RGB-72
Jun 3, 2019

HiFiBiO Therapeutics and Leading Academic Institutions Demonstrate Breakthrough Single-Cell Approach for Novel Biomarker Discovery to Combat Cancer

< 1 … 11 12 13 14 15 … 18 >

oncoverity logo

© 2025 HiFiBiO Therapeutics, Inc.
All Rights Reserved.

Contact

contact@hifibio.com 237 Putnam Ave
Cambridge, MA 02139

Follow Us

Legal

Privacy Policy
Disclaimer
logo
  • About
    • Company Overview
    • Leadership
    • Scientific Advisory Board
    • Board of Directors
    • Scientific Founders
    • Contact
  • Pipeline
    • Overview
    • Overview
    • Programs
      • EMUNKITUG (HFB200301)
      • HFB200603
      • NUVUSTOTUG (HFB301001)
      • HFB200604
      • HFB3024
  • DIS® Platform
  • Partnering
  • News
  • Join Us